Refine your search

Content type
Tags
Firm name
Author
Jurisdiction
Language

1,231 results found

Article
Ask Lexy

Zhong Lun Law Firm | China | 2 Aug 2022

生物医药企业投资中的人类遗传资源合规分析

近年来,随着生物医药行业强劲发展以及国家政策鼓励,已有一百多家生物医药企业申报科创板上市。在生物医药企业上市过程中,除惯常问题外…
Analysis PRO In-house
Ask Lexy

Lexology PRO | European Union, Italy, Netherlands, etc. | 19 Jul 2021

Dutch enforcer issues first excessive pricing fine

The Dutch competition authority has fined Leadiant Biosciences €17.9 million for charging excessively high prices for a drug used to treat a rare genetic metabolic disorder, marking the first time it has ever imposed a penalty for such an infringement.
Analysis PRO In-house
Ask Lexy

Lexology PRO | United Kingdom | 15 Jul 2021

UK hits pharma companies with £266 million fines for overcharging health service

The UK’s Competition and Markets Authority has fined four drugmakers over £266 million for inflating the price of a life-saving drug by over 10,000% and preventing the entry of competing medicines.
Analysis PRO In-house
Ask Lexy

Lexology PRO | European Union, United Kingdom | 25 May 2021

UK NCA: Bribery and corruption risk to rise

In a new report, the agency has warned that criminals are using encrypted messaging services to thwart its investigations, that fintech banks are popular among money launderers, and that the pandemic and Brexit may lead to increased corruption risks for UK companies.
Article
Ask Lexy

Kilpatrick Townsend & Stockton LLP | European Union, Global, United Kingdom, etc. | 11 Feb 2021

Should We Require Human Inventorship? Submit Your Amicus Brief by March

A variety of artificial intelligence (AI) technologies exist and are being used in biopharma (e.g., discovery and development of drugs, optimization…
Article
Ask Lexy

Kilpatrick Townsend & Stockton LLP | USA | 21 Dec 2020

Is compulsory licensing the right tool that will allow the executive branch to control drug pricing?

Prescription drug prices, and means by which the Executive Branch might reduce them absent legislative action, were a hot topic during the 2020…
Article
Ask Lexy

Kramer Levin Naftalis & Frankel LLP | USA | 30 Nov 2020

Third-Generation Vaccines Take Center Stage in Battle Against COVID-19

The biopharmaceutical industry is at the forefront of COVID-19 news due to major advances in vaccine development. Now, more than a year since the…
Article
Ask Lexy

Carpmaels & Ransford LLP | European Union | 26 Jun 2020

How the COVID-19 Pandemic can disrupt life sciences patenting and what you can do about it

The COVID-19 pandemic has caused severe disruptions to many businesses around the world. Pharmaceutical and biotechnology companies have perhaps felt…
Article
Ask Lexy

LexOrbis | India | 2 Jun 2020

Trends in biopharma and biosimilar patents in India

Legal protection for IP rights in the science and technology domain is a topic of long debate around the world, particularly regarding those…
Article
Ask Lexy

Kramer Levin Naftalis & Frankel LLP | USA | 29 Apr 2020

Biopharma Develops Antibody and Stem Cell Therapies in the Fight Against COVID-19

SARS-CoV-2, the virus that causes COVID-19, is a novel coronavirus never before seen in humans. To date, it has caused 60,000 deaths in the United…
Previous page 1 2 3 ...